Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. News
Jul 23, 2025 - businesswire.com
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
May 13, 2025 - businesswire.com
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
Feb 14, 2025 - businesswire.com
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
Dec 23, 2024 - businesswire.com
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Anebulo Pharmaceuticals, Inc. Quantitative Score
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Anebulo Pharmaceuticals, Inc. Financials
Table Compare
Compare ANEB metrics with: | |||
|---|---|---|---|
Earnings & Growth | ANEB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ANEB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ANEB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ANEB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Anebulo Pharmaceuticals, Inc. Income
Anebulo Pharmaceuticals, Inc. Balance Sheet
Anebulo Pharmaceuticals, Inc. Cash Flow
Anebulo Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Anebulo Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer |
| Mr. Richard Anthony Cunningham | Chief Executive Officer & Director |
| Mr. Daniel V. George | Acting Chief Financial Officer & Secretary |
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer | 1959 | 492.76K | |
| Mr. Richard Anthony Cunningham | Chief Executive Officer & Director | Male | 1971 | 452.06K |
| Mr. Daniel V. George | Acting Chief Financial Officer & Secretary | Male | 1970 | 194.25K |
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman | 1973 | 11K |
Anebulo Pharmaceuticals, Inc. Insider Trades
| Date | 4 Apr |
| Name | Lawler Joseph F. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 4 Apr |
| Name | Lawler Joseph F. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 13236 |
| Date | 4 Apr |
| Name | SHAH BIMAL R. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 4 Apr |
| Name | SHAH BIMAL R. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 6618 |
| Date | 4 Apr |
| Name | Cundy Kenneth C |
| Role | Chief Scientific Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 115037 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 4 Apr | Lawler Joseph F. | Director, 10 percent owner | Acquired | A-Award | 25000 |
| 4 Apr | Lawler Joseph F. | Director, 10 percent owner | Acquired | A-Award | 13236 |
| 4 Apr | SHAH BIMAL R. | Director | Acquired | A-Award | 25000 |
| 4 Apr | SHAH BIMAL R. | Director | Acquired | A-Award | 6618 |
| 4 Apr | Cundy Kenneth C | Chief Scientific Officer | Acquired | A-Award | 115037 |